TP53 and cancer: Remarkably, in these cells, profound transgenic p53 expression was restored by treatment with the DNA-damaging bleomycin family antibiotic zeocin, which demonstrates efficiency of the transposon system and furthermore suggests that cancer cells with stable karyotype are also a legitimate target for p53 gene therapy.